These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22507929)

  • 1. Treatment of MDR-TB: is hepatotoxicity a problem?
    Loddenkemper R; Schaberg T
    Int J Tuberc Lung Dis; 2012 May; 16(5):571. PubMed ID: 22507929
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome.
    Keshavjee S; Gelmanova IY; Shin SS; Mishustin SP; Andreev YG; Atwood S; Furin JJ; Miller A
    Int J Tuberc Lung Dis; 2012 May; 16(5):596-603. PubMed ID: 22410436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A death associated with therapy for nosocomially acquired multidrug-resistant tuberculosis.
    Weltman AC; DiFerdinando GT; Washko R; Lipsky WM
    Chest; 1996 Jul; 110(1):279-81. PubMed ID: 8681641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The problem of drug resistance in tuberculosis.
    Kahana LM
    Chest; 1996 Jul; 110(1):8-9. PubMed ID: 8681671
    [No Abstract]   [Full Text] [Related]  

  • 5. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis.
    Younossian AB; Rochat T; Ketterer JP; Wacker J; Janssens JP
    Eur Respir J; 2005 Sep; 26(3):462-4. PubMed ID: 16135729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity.
    Patel H; Pawara R; Pawara K; Ahmed F; Shirkhedkar A; Surana S
    Tuberculosis (Edinb); 2019 Jul; 117():79-84. PubMed ID: 31378273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 21-year-old woman with flank pain.
    Siddiqui MA; Thompson RL
    Mayo Clin Proc; 2006 May; 81(5):673-6. PubMed ID: 16706265
    [No Abstract]   [Full Text] [Related]  

  • 8. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis.
    Lee SS; Lee CM; Kim TH; Kim JJ; Lee JM; Kim HJ; Ha CY; Kim HJ; Jung WT; Lee OJ; Kim DY
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):800-5. PubMed ID: 27155184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.
    Warmelink I; ten Hacken NH; van der Werf TS; van Altena R
    Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin induced encephalopathy in disseminated tuberculosis: A case report.
    Mittal GK; Reddy VASK; Akhtar SM; Kaur H
    Indian J Tuberc; 2020 Jul; 67(3):423-425. PubMed ID: 32825886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New Drugs for the Treatment of Multidrug-resistant Tuberculosis (MDR-TB)].
    Schaberg T; Otto-Knapp R; Bauer T
    Pneumologie; 2015 May; 69(5):282-6. PubMed ID: 25970122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regarding "Management of antitubercular drug-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal".
    Anupa KC; Bista D
    Kathmandu Univ Med J (KUMJ); 2005; 3(3):310. PubMed ID: 18661667
    [No Abstract]   [Full Text] [Related]  

  • 15. When students become patients: TB disease among medical undergraduates in Cape Town, South Africa.
    Van der Westhuizen HM; Dramowski A
    S Afr Med J; 2017 May; 107(6):475-479. PubMed ID: 28604316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis.
    Hsu HL; Bai KJ; Chiang YC; Lin SJ; Yu MC
    J Formos Med Assoc; 2010 Dec; 109(12):923-7. PubMed ID: 21195892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.
    Feja K; McNelley E; Tran CS; Burzynski J; Saiman L
    Pediatr Infect Dis J; 2008 Oct; 27(10):907-12. PubMed ID: 18756183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho.
    Satti H; Mafukidze A; Jooste PL; McLaughlin MM; Farmer PE; Seung KJ
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):468-72. PubMed ID: 22326109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR-TB in Eastern Europe in the era of the TB elimination action framework.
    Dudnyk A; Butov D; Crudu V; Lange C; Chesov D
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):2-3. PubMed ID: 28157456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.